TheStreet upgraded shares of AngioDynamics (NASDAQ:ANGO) from a c rating to a b rating in a research report released on Wednesday morning, TheStreetRatingsTable reports.
A number of other equities research analysts have also recently issued reports on ANGO. BidaskClub upgraded Westport Fuel Systems from a hold rating to a buy rating in a report on Friday. ValuEngine cut Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. Finally, Zacks Investment Research upgraded Investar from a hold rating to a buy rating and set a $27.00 price target for the company in a research note on Tuesday, June 4th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $21.50.
Shares of NASDAQ:ANGO opened at $21.68 on Wednesday. AngioDynamics has a 12-month low of $18.11 and a 12-month high of $25.48. The company has a market capitalization of $814.66 million, a PE ratio of 26.12 and a beta of 0.69. The stock’s 50 day moving average price is $19.62. The company has a current ratio of 4.30, a quick ratio of 1.70 and a debt-to-equity ratio of 0.20.
AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Wednesday, July 10th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.01). AngioDynamics had a return on equity of 5.58% and a net margin of 17.06%. The firm had revenue of $96.30 million for the quarter, compared to the consensus estimate of $92.34 million. During the same quarter in the prior year, the firm earned $0.20 EPS. The company’s revenue was up 9.1% on a year-over-year basis. On average, analysts forecast that AngioDynamics will post 0.27 earnings per share for the current year.
Several hedge funds have recently modified their holdings of the stock. Thrivent Financial for Lutherans boosted its stake in shares of AngioDynamics by 2.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 26,360 shares of the medical instruments supplier’s stock valued at $531,000 after buying an additional 579 shares during the period. Advisor Group Inc. boosted its stake in shares of AngioDynamics by 21.4% in the fourth quarter. Advisor Group Inc. now owns 3,405 shares of the medical instruments supplier’s stock valued at $68,000 after buying an additional 601 shares during the period. Texas Permanent School Fund boosted its stake in shares of AngioDynamics by 3.8% in the first quarter. Texas Permanent School Fund now owns 25,215 shares of the medical instruments supplier’s stock valued at $576,000 after buying an additional 923 shares during the period. Nisa Investment Advisors LLC boosted its stake in shares of AngioDynamics by 100.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,200 shares of the medical instruments supplier’s stock valued at $43,000 after buying an additional 1,100 shares during the period. Finally, PNC Financial Services Group Inc. boosted its stake in shares of AngioDynamics by 28.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,315 shares of the medical instruments supplier’s stock valued at $107,000 after buying an additional 1,181 shares during the period. Institutional investors and hedge funds own 98.46% of the company’s stock.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Further Reading: What are Bollinger Bands?
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.